New research shows that a study of the immunotherapy treatment Crenezumab has found it can reduce levels of the protein amyloid, associated with dementia.

A phase 1 trial, reported in Nature Communications, has found that blood‒brain barrier (BBB) can be non-invasively and reversibly opened in five patients with Alzheimer’s disease.

New research shows that a potential new drug to treat Alzheimer’s disease, Lanabecestat, has failed a phase 2/3 trial.

New research shows that air pollution could have an effect on cognitive ageing.

Research from the Systolic Blood Pressure Intervention Trial (SPRINT) shows that treatment to lower blood pressure can reduce Mild Cognitive Impairment (MCI).

Two new studies have suggest that opioid-based painkillers can cause harmful side effects for people with dementia.